Personalized treatment of sezary syndrome by targeting a novel ctla4:Cd28 fusion

Aleksandar D Sekulic, Winnie S. Liang, Waibhav Tembe, Tyler Izatt, Semyon Kruglyak, Jeffrey A. Kiefer, Lori Cuyugan, Victoria Zismann, Christophe Legendre, Mark R. Pittelkow, John J. Gohmann, Fernando R. De Castro, Jeffrey Trent, John Carpten, David W. Craig, Timothy K. McDaniel

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Matching molecularly targeted therapies with cancer subtype-specific gene mutations is revolutionizing oncology care. However, for rare cancers this approach is problematic due to the often poor understanding of the disease’s natural history and phenotypic heterogeneity, making treatment of these cancers a particularly unmet medical need in clinical oncology. Advanced Sezary syndrome (SS), an aggressive, exceedingly rare variant of cutaneous T-cell lymphoma (CTCL) is a prototypical example of a rare cancer. Through whole genome and RNA sequencing (RNA-seq) of a SS patient’s tumor we discovered a highly expressed gene fusion between CTLA4 (cytotoxic T lymphocyte antigen 4) and CD28 (cluster of differentiation 28), predicting a novel stimulatory molecule on the surface of tumor T cells. Treatment with the CTLA4 inhibitor ipi-limumab resulted in a rapid clinical response. Our findings suggest a novel driver mechanism for SS, and cancer in general, and exemplify an emerging model of cancer treatment using exploratory genomic analysis to identify a personally targeted treatment option when conventional therapies are exhausted.

Original languageEnglish (US)
Pages (from-to)130-136
Number of pages7
JournalMolecular Genetics and Genomic Medicine
Volume3
Issue number2
DOIs
StatePublished - Jan 1 2015

Fingerprint

Sezary Syndrome
Neoplasms
CTLA-4 Antigen
Therapeutics
RNA Sequence Analysis
Cutaneous T-Cell Lymphoma
Medical Oncology
Gene Fusion
Natural History
Genome
T-Lymphocytes
Mutation

Keywords

  • CD28
  • CTLA4
  • Sezary syndrome

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Sekulic, A. D., Liang, W. S., Tembe, W., Izatt, T., Kruglyak, S., Kiefer, J. A., ... McDaniel, T. K. (2015). Personalized treatment of sezary syndrome by targeting a novel ctla4:Cd28 fusion. Molecular Genetics and Genomic Medicine, 3(2), 130-136. https://doi.org/10.1002/mgg3.121

Personalized treatment of sezary syndrome by targeting a novel ctla4:Cd28 fusion. / Sekulic, Aleksandar D; Liang, Winnie S.; Tembe, Waibhav; Izatt, Tyler; Kruglyak, Semyon; Kiefer, Jeffrey A.; Cuyugan, Lori; Zismann, Victoria; Legendre, Christophe; Pittelkow, Mark R.; Gohmann, John J.; De Castro, Fernando R.; Trent, Jeffrey; Carpten, John; Craig, David W.; McDaniel, Timothy K.

In: Molecular Genetics and Genomic Medicine, Vol. 3, No. 2, 01.01.2015, p. 130-136.

Research output: Contribution to journalArticle

Sekulic, AD, Liang, WS, Tembe, W, Izatt, T, Kruglyak, S, Kiefer, JA, Cuyugan, L, Zismann, V, Legendre, C, Pittelkow, MR, Gohmann, JJ, De Castro, FR, Trent, J, Carpten, J, Craig, DW & McDaniel, TK 2015, 'Personalized treatment of sezary syndrome by targeting a novel ctla4:Cd28 fusion', Molecular Genetics and Genomic Medicine, vol. 3, no. 2, pp. 130-136. https://doi.org/10.1002/mgg3.121
Sekulic, Aleksandar D ; Liang, Winnie S. ; Tembe, Waibhav ; Izatt, Tyler ; Kruglyak, Semyon ; Kiefer, Jeffrey A. ; Cuyugan, Lori ; Zismann, Victoria ; Legendre, Christophe ; Pittelkow, Mark R. ; Gohmann, John J. ; De Castro, Fernando R. ; Trent, Jeffrey ; Carpten, John ; Craig, David W. ; McDaniel, Timothy K. / Personalized treatment of sezary syndrome by targeting a novel ctla4:Cd28 fusion. In: Molecular Genetics and Genomic Medicine. 2015 ; Vol. 3, No. 2. pp. 130-136.
@article{c2434c05363f44fb9117c7df7e81e30e,
title = "Personalized treatment of sezary syndrome by targeting a novel ctla4:Cd28 fusion",
abstract = "Matching molecularly targeted therapies with cancer subtype-specific gene mutations is revolutionizing oncology care. However, for rare cancers this approach is problematic due to the often poor understanding of the disease’s natural history and phenotypic heterogeneity, making treatment of these cancers a particularly unmet medical need in clinical oncology. Advanced Sezary syndrome (SS), an aggressive, exceedingly rare variant of cutaneous T-cell lymphoma (CTCL) is a prototypical example of a rare cancer. Through whole genome and RNA sequencing (RNA-seq) of a SS patient’s tumor we discovered a highly expressed gene fusion between CTLA4 (cytotoxic T lymphocyte antigen 4) and CD28 (cluster of differentiation 28), predicting a novel stimulatory molecule on the surface of tumor T cells. Treatment with the CTLA4 inhibitor ipi-limumab resulted in a rapid clinical response. Our findings suggest a novel driver mechanism for SS, and cancer in general, and exemplify an emerging model of cancer treatment using exploratory genomic analysis to identify a personally targeted treatment option when conventional therapies are exhausted.",
keywords = "CD28, CTLA4, Sezary syndrome",
author = "Sekulic, {Aleksandar D} and Liang, {Winnie S.} and Waibhav Tembe and Tyler Izatt and Semyon Kruglyak and Kiefer, {Jeffrey A.} and Lori Cuyugan and Victoria Zismann and Christophe Legendre and Pittelkow, {Mark R.} and Gohmann, {John J.} and {De Castro}, {Fernando R.} and Jeffrey Trent and John Carpten and Craig, {David W.} and McDaniel, {Timothy K.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1002/mgg3.121",
language = "English (US)",
volume = "3",
pages = "130--136",
journal = "Molecular genetics & genomic medicine",
issn = "2324-9269",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Personalized treatment of sezary syndrome by targeting a novel ctla4:Cd28 fusion

AU - Sekulic, Aleksandar D

AU - Liang, Winnie S.

AU - Tembe, Waibhav

AU - Izatt, Tyler

AU - Kruglyak, Semyon

AU - Kiefer, Jeffrey A.

AU - Cuyugan, Lori

AU - Zismann, Victoria

AU - Legendre, Christophe

AU - Pittelkow, Mark R.

AU - Gohmann, John J.

AU - De Castro, Fernando R.

AU - Trent, Jeffrey

AU - Carpten, John

AU - Craig, David W.

AU - McDaniel, Timothy K.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Matching molecularly targeted therapies with cancer subtype-specific gene mutations is revolutionizing oncology care. However, for rare cancers this approach is problematic due to the often poor understanding of the disease’s natural history and phenotypic heterogeneity, making treatment of these cancers a particularly unmet medical need in clinical oncology. Advanced Sezary syndrome (SS), an aggressive, exceedingly rare variant of cutaneous T-cell lymphoma (CTCL) is a prototypical example of a rare cancer. Through whole genome and RNA sequencing (RNA-seq) of a SS patient’s tumor we discovered a highly expressed gene fusion between CTLA4 (cytotoxic T lymphocyte antigen 4) and CD28 (cluster of differentiation 28), predicting a novel stimulatory molecule on the surface of tumor T cells. Treatment with the CTLA4 inhibitor ipi-limumab resulted in a rapid clinical response. Our findings suggest a novel driver mechanism for SS, and cancer in general, and exemplify an emerging model of cancer treatment using exploratory genomic analysis to identify a personally targeted treatment option when conventional therapies are exhausted.

AB - Matching molecularly targeted therapies with cancer subtype-specific gene mutations is revolutionizing oncology care. However, for rare cancers this approach is problematic due to the often poor understanding of the disease’s natural history and phenotypic heterogeneity, making treatment of these cancers a particularly unmet medical need in clinical oncology. Advanced Sezary syndrome (SS), an aggressive, exceedingly rare variant of cutaneous T-cell lymphoma (CTCL) is a prototypical example of a rare cancer. Through whole genome and RNA sequencing (RNA-seq) of a SS patient’s tumor we discovered a highly expressed gene fusion between CTLA4 (cytotoxic T lymphocyte antigen 4) and CD28 (cluster of differentiation 28), predicting a novel stimulatory molecule on the surface of tumor T cells. Treatment with the CTLA4 inhibitor ipi-limumab resulted in a rapid clinical response. Our findings suggest a novel driver mechanism for SS, and cancer in general, and exemplify an emerging model of cancer treatment using exploratory genomic analysis to identify a personally targeted treatment option when conventional therapies are exhausted.

KW - CD28

KW - CTLA4

KW - Sezary syndrome

UR - http://www.scopus.com/inward/record.url?scp=84971513662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971513662&partnerID=8YFLogxK

U2 - 10.1002/mgg3.121

DO - 10.1002/mgg3.121

M3 - Article

VL - 3

SP - 130

EP - 136

JO - Molecular genetics & genomic medicine

JF - Molecular genetics & genomic medicine

SN - 2324-9269

IS - 2

ER -